Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma
NCT06209619Phase 1Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of golcadomide in non-Hodgkin lymphoma (NHL). Primary endpoints: Incidence of adverse events and Maximum tolerated dose. Started Jan 2024; status: recruiting.
02
Drugs
golcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06209619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209619.